Search

everythinglearnresearchcommunity

for

Search:↓

A user stopped using RU58841 after discovering their girlfriend's unplanned pregnancy, expressing concern about potential harm to the baby. Others advised consulting a doctor, waiting for health scans, and considering switching to oral finasteride or natural supplements like saw palmetto.

RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.

Finasteride can reduce neuroactive steroids, causing side effects like depression, anxiety, and sexual dysfunction. Some users experience persistent symptoms after stopping finasteride, while others use alternative treatments like topical solutions.

The user is using a combination of hair loss treatments including dutasteride, minoxidil, RU58841, low-level laser therapy, ketokonozole, supplements, Viviscal, Nutrafol, microneedling, PRP, and scalp Botox injections, but is still experiencing hair shedding and thinning. Despite being on this regimen for two years, the user's hair condition is worsening, and they are seeking advice on what else they can do.

The user plans to start a 12-month finasteride treatment to combat aggressive hair loss, with regular monitoring of thyroid levels, testosterone, DHT, liver enzymes, PSA, and iron levels. They seek advice on additional monitoring and aim to balance results with minimal side effects.

A user ingested RU58841 orally and experienced severe heart and breathing issues, requiring emergency medical assistance. They concluded that MV supplements is a legitimate supplier but warned of the serious side effects.

The user is considering adding RU58841 to their current hair loss treatment of finasteride and minoxidil, but is concerned about potential side effects like hairline recession and shedding. Some users report positive results with RU58841, while others experience side effects such as chest pain and dizziness.

France is considering reviewing finasteride and dutasteride due to concerns about their safety, but a ban in the EU is unlikely due to regulatory hurdles. Many users express frustration over the potential ban, emphasizing the effectiveness of finasteride for hair loss and criticizing the influence of anecdotal evidence on public health policy.

A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.

The user is documenting their hair loss journey, using oral finasteride since January 2025, and plans to add microneedling and rosemary oil. They have experienced no further hair loss but no gains, and are considering oral minoxidil due to having pets.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

The user discovered their previous hair loss medication was counterfeit and switched to Propecia, which significantly lowered their DHT levels. They plan to continue using Propecia and add oral Minoxidil to their routine for better results.

The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.

Hair loss is linked to a higher rate of body dysmorphic disorder (BDD), OCD, and depression. Finasteride and dutasteride are not linked to increased suicidal risk, though some users report mental health side effects.

A user on dutasteride for hair loss noticed hair regrowth on their head but a significant reduction in body hair growth. They plan to switch to finasteride and dutasteride and are considering testosterone replacement therapy but are concerned about its effects on hair growth.

The user is experiencing hair loss despite using dutasteride, minoxidil, and ketoconazole shampoo, and is concerned about continued shedding. Suggestions include checking for nutrient deficiencies, consulting a dermatologist, and considering other potential causes like seborrheic dermatitis or telogen effluvium.

A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.

A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.

Minoxidil, finasteride, and RU58841 are discussed as treatments for hair loss. Concerns about AI-generated content accuracy and misinformation are raised.

Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.

The conversation discusses the comparison of Pyrilutamide Phase II US trial results with 1 mg finasteride for hair loss treatment. It mentions that the total hair count increase in the US trial was not as good as the China trial.

The safety and effectiveness of RU-58841 as a hair loss treatment, with some users reporting side effects like chest pains, while others had positive results. The original research on RU-58841 was likely stopped due to financial issues, not safety concerns.

The conversation is about the availability of the research chemical GT20029 for hair loss treatment and when companies like Anageninc will have it. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

A 25-year-old is experiencing hair thinning despite using 0.5mg oral dutasteride, 0.3% topical finasteride, and 6% topical minoxidil daily for a year. They are considering increasing dutasteride dosage and exploring other treatments like microneedling and KX 826, while seeking further medical opinions on their condition.

A 42-year-old man used finasteride for three years, switched to dutasteride, and added oral minoxidil, resulting in stabilized hair loss and some regrowth, especially with dutasteride. He experienced no side effects and plans to consider a hair transplant in the future.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

A user shared their hair regrowth journey from ages 31 to 39, using finasteride, oral and topical minoxidil, and dutasteride. They experienced significant hair density improvement and temple regrowth, with increased hair growth as the only side effect.

A 41-year-old shared their 195-day hair loss treatment progress using finasteride and minoxidil, initially topical and later oral, along with microneedling. They reported positive results and expressed satisfaction with the current regimen.

The post is about Bryan Johnson's hair loss regimen, which includes dutasteride mesotherapy, minoxidil, microneedling, and red laser therapy. The conversation includes discussions about the effectiveness of topical dutasteride and speculation about whether Bryan Johnson has had a hair transplant.